Masako Saito
Chuo, 1038411, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Effects of renal impairment on the pharmacokinetics, safety, and tolerability of pudexacianinium (ASP5354) after IV administration: a mechanistic exploration.
Journal: European journal of clinical pharmacology
Published: November 18, 2025
Concentration-QTc Modeling to Support Clinical Development of Fezolinetant.
Journal: Clinical pharmacology in drug development
Published: June 23, 2025
Pharmacokinetics, Tolerability, and Biomarker Profile of the Neurokinin 3 Receptor Antagonist Fezolinetant in Healthy Japanese Individuals: A 2-Part, Randomized, Phase 1 Study.
Journal: Clinical pharmacology in drug development
Published: March 26, 2025
Recent Utilization of Pediatric Extrapolation and Modeling and Simulation Approaches in Pediatric Drug Development in Japan.
Journal: Journal of clinical pharmacology
Published: January 30, 2025
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Muscarinic M3 Receptor-Positive Allosteric Modulator ASP8302 Following Single and Multiple Ascending Oral Doses in Healthy Volunteers.
Journal: Clinical pharmacology in drug development
Published: March 22, 2024
Population Pharmacokinetic Modeling and Simulation of Pudexacianinium (ASP5354) for Dose Setting of a Phase 2 First-in-Patient Study: A Novel Imaging Agent for Intraoperative Ureter Visualization during Abdominopelvic Surgery.
Journal: Clinical pharmacology in drug development
Published: September 12, 2023
Comparison of the Pharmacokinetic and Pharmacodynamic Relationship of Ipragliflozin Between Patients With Type 1 and Type 2 Diabetes Mellitus.
Journal: Clinical therapeutics
Published: April 24, 2020
Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects.
Journal: Clinical drug investigation
Published: April 11, 2020
ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial.
Journal: Arthritis research & therapy
Published: March 28, 2020
Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: November 29, 2019
Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
Journal: British journal of clinical pharmacology
Published: November 02, 2018
Last Updated: 09/26/2026